Lubrizol LifeSciences Announces New Medical Device Applications Lab

(BRK.A), (BRK.B)

Berkshire Hathaway’s Lubrizol Corporation has announced that its LifeSciences business will feature a new medical device applications lab.

LifeSciences has invested significantly to expand its global development and manufacturing facilities, and the latest investment is a new state-of-the-art medical device applications lab in Brecksville, Ohio.

The lab features applications testing, small-scale compounding as well as injection molding for long-term implantables. The 1,800-square foot facility will also focus on accelerated R&D, from polymers to device scale up and testing in a short period of time.

“The new applications lab is another commitment to healthcare companies looking for a full-service development partner. We continue to invest in the right areas to provide valuable offerings where our customers are experiencing the most growth,” states Uwe Winzen, general manager, Lubrizol LifeSciences. “When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process.”

Offering more than 90 years of science and technology experience, Lubrizol is uniquely structured to partner with medical device manufacturers by providing proactive innovation, speed to market, and expertise for the most demanding projects. From materials to development and manufacturing, or anything in between – Lubrizol LifeSciences is equipped to support the needs of customers worldwide.

© 2019 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.